Search Results

Astria Therapeutics, Inc. today announced that it will present final STAR-0215 Phase 1a healthy subject data at the upcoming American Academy of Allergy, Asthma, & Immunology (AAAAI) Annual Meeting in Washington, D.C. on February 23, 2024 at 3:15pm EST.

Intrommune Therapeutics, Inc. today announced data from The First Study To Evaluate Oral Mucosal Immunotherapy (OMIT) For The Treatment Of Food Allergy has been selected as a Late Breaking Poster Presentation at the 2024 American Academy of Allergy, Asthma & Immunology in Washington, DC.

KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting taking place in Washington, DC from February 23-26.

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper) is presenting results from three preclinical studies evaluating briquilimab, at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, being held February 23-26 in Washington, D.C.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that it presented additional data on its phase 3 KONFIDENT trial for sebetralstat, including a more in-depth analysis of sebetralstat efficacy and safety at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Washington, DC.

KalVista Pharmaceuticals, Inc. announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting that took place in Washington, DC.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new analyses of real-world use of oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.